Search results
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
WDTN-TV 2 Dayton· 15 hours agoProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by ...
AstraZeneca removes Covid vaccine after very rare side effect linked to deaths
The US Sun· 3 days agoIt is another sign that the outbreak is consigned to history after the World Health Organisation...
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop...
CNBC· 20 hours agoA health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization...
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoAclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript May 7, 2024 Aclaris...
High Response Rates With Gene Therapies for BCG-Unresponsive Bladder Cancer
MedPage Today· 7 days agoThree-fourths of patients had complete responses, which proved to be durable in most cases
Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
Bloomberg via Yahoo Finance· 2 days ago(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion...
'Pandemic proof' vaccine could beat coronaviruses we don't even know about yet
The US Sun· 4 days agoBRITISH scientists reckon they can make a vaccine for coronaviruses we do not even know about yet....
AstraZeneca withdraws Covid vaccine as demand dives
Medical Xpress· 3 days agoAnglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing COVID vaccine Vaxzevria, one of the first produced in the deadly pandemic,...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
WKBN 27 Youngstown· 4 days ago...neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored trial and regulatory guidance both in H2 2024Selected move-forward Phase 2 dose for IDE397 in MTAP squamous NSCLC, based on clinical efficacy...
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into F
Guru Focus· 6 hours agoSangamo Therapeutics Inc (SGMO, Financial), a leader in genomic medicine, disclosed its 8-K filing on May 9, 2024, revealing detailed insights into its first quarter financials and recent strategic ...